These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 19292973)

  • 1. Proceedings and data from The Schizophrenia Summit: a critical appraisal to improve the management of Schizophrenia.
    Nasrallah HA; Keshavan MS; Benes FM; Braff DL; Green AI; Gur RE; Kane JM; Perkins DO; Weiden PJ; Weinberger DR; Correll CU
    J Clin Psychiatry; 2009; 70 Suppl 1():4-46. PubMed ID: 19292973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Cognitive deficits in first episode psychosis patients and people at risk for psychosis: from diagnosis to treatment].
    Lecardeur L; Meunier-Cussac S; Dollfus S
    Encephale; 2013 May; 39 Suppl 1():S64-71. PubMed ID: 23528322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prodromal schizophrenia: the dilemma of prediction and early intervention.
    Davidson M; Weiser M
    CNS Spectr; 2004 Aug; 9(8):578. PubMed ID: 15273649
    [No Abstract]   [Full Text] [Related]  

  • 4. Toward a better identification and treatment of schizophrenia prodrome.
    Bota RG; Sagduyu K; Filin EE; Bota DA; Munro S
    Bull Menninger Clin; 2008; 72(3):210-27. PubMed ID: 18990056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identifying vulnerability markers in prodromal patients: a step in the right direction for schizophrenia prevention.
    Knowles L; Sharma T
    CNS Spectr; 2004 Aug; 9(8):595-602. PubMed ID: 15273652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early intervention for schizophrenia: the risk-benefit ratio of antipsychotic treatment in the prodromal phase.
    Weiser M
    Am J Psychiatry; 2011 Aug; 168(8):761-3. PubMed ID: 21813489
    [No Abstract]   [Full Text] [Related]  

  • 7. Substance abuse and the management of medication nonadherence in schizophrenia.
    Wilk J; Marcus SC; West J; Countis L; Hall R; Regier DA; Olfson M
    J Nerv Ment Dis; 2006 Jun; 194(6):454-7. PubMed ID: 16772865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroprotection: a therapeutic strategy to prevent deterioration associated with schizophrenia.
    Lieberman JA; Perkins DO; Jarskog LF
    CNS Spectr; 2007 Mar; 12(3 Suppl 4):1-13; quiz 14. PubMed ID: 17329984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Psychosis treatment prior to psychosis onset: ethical issues.
    McGlashan TH
    Schizophr Res; 2001 Aug; 51(1):47-54. PubMed ID: 11479065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Schizophrenia and comorbid substance use disorder: effects of antipsychotics.
    Green AI
    J Clin Psychiatry; 2005; 66 Suppl 6():21-6. PubMed ID: 16107180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is oestrogen neuroprotective?
    Agius M; Hockings H; Wilson C; Lane D
    Psychiatr Danub; 2009 Sep; 21 Suppl 1():120-7. PubMed ID: 19789496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of schizophrenia and comorbid substance abuse: pharmacologic approaches.
    Green AI
    J Clin Psychiatry; 2006; 67 Suppl 7():31-5; quiz 36-7. PubMed ID: 16961422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The diagnosis and assessment of individuals prodromal for schizophrenic psychosis.
    Addington J
    CNS Spectr; 2004 Aug; 9(8):588-94. PubMed ID: 15273651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The psychoses: cluster 3 of the proposed meta-structure for DSM-V and ICD-11.
    Carpenter WT; Bustillo JR; Thaker GK; van Os J; Krueger RF; Green MJ
    Psychol Med; 2009 Dec; 39(12):2025-42. PubMed ID: 19796428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of pharmacotherapy in the prodrome of schizophrenia.
    Remington G; Shammi C
    CNS Spectr; 2004 Aug; 9(8):579-86. PubMed ID: 15273650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical characteristics of schizotypal-related obsessive-compulsive disorder.
    Poyurovsky M; Faragian S; Pashinian A; Heidrach L; Fuchs C; Weizman R; Koran L
    Psychiatry Res; 2008 May; 159(1-2):254-8. PubMed ID: 18378321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beating psychosis to the punch: the treatment options debate.
    Gorman JM
    CNS Spectr; 2004 Aug; 9(8):572. PubMed ID: 15273647
    [No Abstract]   [Full Text] [Related]  

  • 18. Early intervention in schizophrenia: current and future perspectives.
    Keshavan MS; Amirsadri A
    Curr Psychiatry Rep; 2007 Aug; 9(4):325-8. PubMed ID: 17880865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Precursors and prodromata of schizophrenia: findings from the Edinburgh High Risk Study and their literature context.
    Owens DG; Johnstone EC
    Psychol Med; 2006 Nov; 36(11):1501-14. PubMed ID: 16817986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Linkage of cognitive impairments with metabolic disorders in schizophrenia.
    Nasrallah HA
    Am J Psychiatry; 2010 Oct; 167(10):1155-7. PubMed ID: 20889659
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.